Novartis AG
NVS · NYSE
9/29/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $14,358 | $14,836 | $13,620 | $13,558 |
| % Growth | -3.2% | 8.9% | 0.5% | – |
| Cost of Goods Sold | $3,539 | $3,322 | $3,227 | $3,324 |
| Gross Profit | $10,819 | $11,514 | $10,393 | $10,234 |
| % Margin | 75.4% | 77.6% | 76.3% | 75.5% |
| R&D Expenses | $2,944 | $2,727 | $2,366 | $2,842 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3,308 | $3,442 | $3,058 | $3,501 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $66 | $481 | $306 | $361 |
| Operating Expenses | $6,318 | $6,650 | $5,730 | $6,704 |
| Operating Income | $4,501 | $4,864 | $4,663 | $3,530 |
| % Margin | 31.3% | 32.8% | 34.2% | 26% |
| Other Income/Exp. Net | -$305 | -$333 | -$256 | -$245 |
| Pre-Tax Income | $4,196 | $4,531 | $4,407 | $3,285 |
| Tax Expense | $266 | $507 | $798 | $465 |
| Net Income | $3,928 | $4,041 | $3,606 | $2,818 |
| % Margin | 27.4% | 27.2% | 26.5% | 20.8% |
| EPS | 0.62 | 2.07 | 1.83 | 1.42 |
| % Growth | -70% | 13.1% | 28.9% | – |
| EPS Diluted | 0.62 | 2.06 | 1.82 | 1.41 |
| Weighted Avg Shares Out | 1,926 | 1,948 | 1,968 | 1,987 |
| Weighted Avg Shares Out Dil | 1,940 | 1,960 | 1,979 | 2,004 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $281 | $294 | $270 | $273 |
| Depreciation & Amortization | $1,364 | $1,256 | $1,154 | $1,628 |
| EBITDA | $5,841 | $6,076 | $5,831 | $5,188 |
| % Margin | 40.7% | 41% | 42.8% | 38.3% |